论文部分内容阅读
目的：探讨艾司西酞普兰治疗女性更年期抑郁症患者的疗效和安全性。方法将45例女性更年期抑郁症患者按就诊顺序分为两组，研究组22例，口服艾司西酞普兰治疗，对照组23例，予以常规对症治疗，观察8周。治疗前后采用汉密顿抑郁量表评定抑郁症状，副反应量表评定不良反应。结果治疗后两组患者汉密顿抑郁量表评分呈持续性下降，研究组治疗各时点均较对照组下降更显著（P＜0．05）；治疗8周末研究组总有效率为68．2％，对照组为34．8％，研究组显著高于对照组（χ2＝6．14，P ＜0．05）。两组不良反应均较轻微，发生率比较差异无显著性（P＞0．05）。结论艾司西酞普兰治疗女性更年期抑郁症起效快，疗效显著，安全性高，显著优于常规对症治疗，值得临床推广应用。“,”Objective To explore the efficacy and safety of escitalopram in the treatment of female involu‐tional depression (ID) .Methods Forty‐five female ID patients were assigned to two groups according to visiting sequence ,research group (n = 22) took orally escitalopram and control group (n = 23) received routine symptomatic treatment for 8 weeks .Depressive symptoms were assessed with the Hamilton De‐pression Scale (HAMD) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) be‐fore and after treatment .Results After treatment the HAMD scores of both groups lowered continuous‐ly ,so did those at all time‐points of treatment in research than in control group (P< 0 .05) ;at the end of the 8th week total effective rates were respectively 68 .2% in research and 34 .8% in control group ,the for‐mer was significantly higher than the latter (χ2 = 6 .14 ,P 0 .05) .Conclu‐sion Escitalopram takes effect more rapidly ,has an evident effect and higher safety compared with routine symptomatic treatment for female ID ,and deserves clinical generalization and application .